Biotest AG
BIESF · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -39% | 35% | -3.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 11.4% | 26% | 19.4% | 32.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | $0 | -$0 | $0 |
| % Margin | -18.5% | 11.5% | -4.8% | 16.3% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $0 | -$0 | $0 |
| Tax Expense | -$0 | $0 | -$0 | $0 |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -17.2% | -1.7% | -6.2% | 6.2% |
| EPS | -0.55 | -0.094 | -0.25 | 0.24 |
| % Growth | -485.1% | 62.4% | -204.2% | – |
| EPS Diluted | -0.55 | -0.094 | -0.25 | 0.24 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | $0 | $0 |
| % Margin | -7.7% | 5.8% | 1.5% | 22.2% |